The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Myrelez 60 mg solution for injection in pre-filled syringe

Amdipharm LimitedPA1142/039/001

Main Information

Trade NameMyrelez 60 mg solution for injection in pre-filled syringe
Active SubstancesLanreotide
Dosage FormSolution for injection in pre-filled syringe
Licence HolderAmdipharm Limited
Licence NumberPA1142/039/001

Group Information

ATC CodeH01CB03 lanreotide


License statusAuthorised
Licence Issued23/07/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back